Craft
  • Home
  •  / Denali Therapeutics
Denali Therapeutics

Denali Therapeutics

Revenue

$48.7 M

FY, 2021

Market Capitalization

$3.5 B

2022-09-20

Denali Therapeutics Summary

Company summary

Overview
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
Type
Public
Founded
2015
HQ
South San Francisco, CA, US | view all locations
Website
http://denalitherapeutics.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Ryan Watts

    Ryan Watts, Chief Executive Officer

  • Ryan Watts

    Ryan Watts, Chief Executive Officer, Director

    • Carole Ho

      Carole Ho, Chief Medical Officer

    • Steve Krognes

      Steve Krognes, Chief Financial Officer

      LocationsView all

      1 location detected

      • South San Francisco, CA HQ

        United States

        151 Oyster Point Blvd

      Denali Therapeutics Financials

      Summary financials

      Revenue (Q2, 2022)
      $52.5M
      Net income (Q2, 2022)
      ($58.8M)
      Cash (Q2, 2022)
      $155.1M
      EBIT (Q2, 2022)
      ($61.4M)
      Enterprise value
      $3.4B

      Footer menu